Update on Morphic Medical Inc.

AI SummaryClose X

Crystal Amber Fund Limited has invested an additional US$8 million, approximately £5.9 million, into Morphic Medical Inc. (MMI), bringing its total holding to 418,944,800 shares, representing 97.8% of MMI's issued share capital. MMI's Reset® device, which treats obesity and type 2 diabetes, has received European CE mark and UK regulatory approval, with distribution agreements in place for Spain, Belgium, Netherlands, Czech Republic, and the Middle East. Patient enrolment for the US Step-1 study is ongoing, with FDA approval anticipated in 2028 or 2029, and MMI is preparing for scaled manufacturing to meet future demand. Discussions with potential investors, including large medical device companies, are underway, with MMI directors believing any investment would be at a premium to its current carrying value. Crystal Amber is also advancing proposals for a change of strategy and investment manager, with a circular expected to be sent to shareholders shortly.

Disclaimer*

UK 100

Latest directors dealings